Trending Now - Regeneron Partners With Trump for Free Hearing Loss Treatment

WHO:

CNBC - U.S. President Donald Trump (C) speaks during an event on advancing health care affordability.

NOTUS - Regeneron is the pharmaceutical company involved in the deal.

NOTUS - Chris Klomp is the CMS deputy administrator involved in the negotiations.

WHAT:

CNBC - Regeneron agreed to lower U.S. drug prices for some Americans as part of a deal with Trump.

CNBC - Regeneron will offer the first hearing-loss gene therapy, Otarmeni, for free to eligible U.S. patients.

NOTUS - Regeneron has agreed to reduce Medicaid prices for its current and future medications.

NOTUS - Regeneron will sell Praluent, a cholesterol-lowering drug, for $225.

NOTUS - Regeneron committed almost $10 billion to boost domestic manufacturing capabilities.

CNBC - The gene therapy Otarmeni is estimated to generate peak sales of $130 million.

WHERE:

CNBC - The announcement took place in the Oval Office of the White House in Washington, DC.

NOTUS - The drug pricing portal, TrumpRx, will list the discounted medications.

WHEN:

CNBC - The deal was announced on April 23, 2026.

CNBC - The FDA approved the gene therapy Otarmeni on April 23, 2026.

NOTUS - The initial agreement with Pfizer occurred in September 2025.

WHY:

CNBC - The deal is part of Trump's "most favored nation" effort to tie U.S. drug prices to the lowest prices in other developed nations.

NOTUS - The deal was part of a yearlong pressure campaign for pharmaceutical makers to discount drugs in exchange for tariff relief.

HOW:

CNBC - The agreements exempt the companies from tariffs for three years, including Trump's planned up to 100% levies on some pharmaceutical products.

NOTUS - The deals were brokered by Chris Klomp, who was recently appointed to stabilize the Department of Health and Human Services.

(UPDATED April 24, 2026 09:27 UTC)

President Trump announced a significant deal with Regeneron on Thursday, aimed at lowering drug prices for Americans, which includes offering the first hearing-loss gene therapy, Otarmeni, for free to eligible patients. As part of this agreement, Regeneron will also reduce Medicaid prices for its medications and sell its cholesterol-lowering drug, Praluent, for $225, while committing nearly $10 billion to enhance domestic manufacturing. The negotiations, led by CMS deputy administrator Chris Klomp, are part of Trump's broader initiative to align U.S. drug prices with the lowest prices in other developed nations, exempting the companies from tariffs for three years.